Synovetin OA is a groundbreaking treatment for canine OA that is designed to treat the underlying inflammation to provide up to 1 year of relief with just 1 treatment

Synovetin OA is an intra-articular treatment that leverages the unique radioisotope tin-117m to address inflammation within the joint. Synovetin OA is the only treatment designed to directly target synovial inflammation, the driver of pain and joint damage, and help prevent further joint damage, especially when used earlier in the disease.4-6

Designed to treat the inflammation that fuels progressive joint destruction

Supports long-term
joint health

Provides up to 1 full year of pain relief with just 1 treatment

Restores a dog’s joyful mobility and playful companionship

What is Synovetin OA®?

Synovetin OA is a first-line choice best used in early OA management to relieve the pain and help preserve the health of the joint.

Up to 1 full year of relief with just 1 simple, safe treatment

Compared with other canine OA treatments that require daily or monthly dosing, Synovetin OA is a convenient option that also eliminates compliance problems.

Peer reviewed, published data prove up to 1 year of relief with just 1 treatment4

Synovetin OA provides increasing pain relief and improved mobility over a year, yet with no active tin-117m remaining in the joint.

*Overall treatment success based on a composite of force plate, Canine Brief Pain Index (CBPI), and clinician assessments for the label dose.

Exceptionally safe with no systemic side effects— so you can treat with confidence7

No effect on bone, cartilage, ligaments, or other joint structures

No systemic distribution with no systemic or adverse events

CBC and serum chemistry values remained within normal limits

Blood, urine, and fecal counts show >99.1% is retained in the injected joint

No effect on bone, cartilage, ligaments, or other joint structures

CBC and serum chemistry values remained within normal limits

No systemic distribution with no systemic or adverse events

Blood, urine, and fecal counts show >99.1% is retained in the injected joint

Package Insert

Consumer Website

Veterinary Brochure

Tin-117m, the active ingredient in Synovetin OA, has been shown to slow OA progression in rodent models

Learn More: See the poster presented the Society of Nuclear Medicine and Molecular Imaging Annual Conference.

keyboard_arrow_up